Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENERGY 3 study of INZ-701 in children with ENPP1 deficiency
2023-507382-26-00Phase 3Completed
- Sponsor
- Inozyme Pharma
- Start
- May 2024
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 3, randomised, open-label trial of INZ-701 in ENPP1 deficiency (2 arms), sponsored by Inozyme Pharma. Primary endpoints: Change from baseline in plasma PPi concentration through Week 52 and RGI-C global score through Week 52. Started May 2024; status: completed.
02
Drugs
INZ-701
03
Conditions
ENPP1 deficiency
Beyond the preview
Go deeper on 2023-507382-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507382-26-00.